Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

The role of Fc receptors in HIV prevention and therapy.

Boesch AW, Brown EP, Ackerman ME.

Immunol Rev. 2015 Nov;268(1):296-310. doi: 10.1111/imr.12339. Review.

2.

Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.

Gohain N, Tolbert WD, Acharya P, Yu L, Liu T, Zhao P, Orlandi C, Visciano ML, Kamin-Lewis R, Sajadi MM, Martin L, Robinson JE, Kwong PD, DeVico AL, Ray K, Lewis GK, Pazgier M.

J Virol. 2015 Sep;89(17):8840-54. doi: 10.1128/JVI.01232-15. Epub 2015 Jun 17.

3.

Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies.

Sips M, Krykbaeva M, Diefenbach TJ, Ghebremichael M, Bowman BA, Dugast AS, Boesch AW, Streeck H, Kwon DS, Ackerman ME, Suscovich TJ, Brouckaert P, Schacker TW, Alter G.

Mucosal Immunol. 2016 Nov;9(6):1584-1595. doi: 10.1038/mi.2016.12. Epub 2016 Feb 17.

4.

Antibody Functional Assays as Measures of Fc Receptor-Mediated Immunity to HIV - New Technologies and their Impact on the HIV Vaccine Field.

Wines BD, Billings H, Mclean MR, Kent SJ, Hogarth PM.

Curr HIV Res. 2017;15(3):202-215. doi: 10.2174/1570162X15666170320112247. Review.

5.

HIV/AIDS: allied responses.

Mascola JR.

Nature. 2007 Sep 6;449(7158):29-30. No abstract available.

PMID:
17805280
7.

Antibody-Based Preventive and Therapeutic Strategies Against HIV.

Fabra-Garcia A, Beltran C, Sanchez-Merino V, Yuste E.

Curr HIV Res. 2016;14(3):260-9. Review.

PMID:
26957200
8.

Fc receptor but not complement binding is important in antibody protection against HIV.

Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR.

Nature. 2007 Sep 6;449(7158):101-4.

PMID:
17805298
9.

Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles.

Brown EP, Dowell KG, Boesch AW, Normandin E, Mahan AE, Chu T, Barouch DH, Bailey-Kellogg C, Alter G, Ackerman ME.

J Immunol Methods. 2017 Apr;443:33-44. doi: 10.1016/j.jim.2017.01.010. Epub 2017 Feb 3.

11.

Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Vargas-Inchaustegui DA, Robert-Guroff M.

Curr HIV Res. 2013 Jul;11(5):407-20.

PMID:
24191937
12.

Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission.

Cheeseman HM, Carias AM, Evans AB, Olejniczak NJ, Ziprin P, King DF, Hope TJ, Shattock RJ.

PLoS One. 2016 May 10;11(5):e0154656. doi: 10.1371/journal.pone.0154656. eCollection 2016.

13.

Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.

Excler JL, Ake J, Robb ML, Kim JH, Plotkin SA.

Clin Vaccine Immunol. 2014 Aug;21(8):1023-36. doi: 10.1128/CVI.00230-14. Epub 2014 Jun 11. Review.

14.

Opportunities to exploit non-neutralizing HIV-specific antibody activity.

Ackerman ME, Alter G.

Curr HIV Res. 2013 Jul;11(5):365-77. Review.

15.

Role of humoral immunity in host defense against HIV.

Baum LL.

Curr HIV/AIDS Rep. 2010 Feb;7(1):11-8. doi: 10.1007/s11904-009-0036-6. Review.

16.

Editorial: Fc receptor-mediated effector functions in the humoral control of HIV-1 infection.

DeVico A.

Curr HIV Res. 2013 Jul;11(5):343-4. No abstract available.

PMID:
24191941
17.

Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.

Huang Y, Ferrari G, Alter G, Forthal DN, Kappes JC, Lewis GK, Love JC, Borate B, Harris L, Greene K, Gao H, Phan TB, Landucci G, Goods BA, Dowell KG, Cheng HD, Bailey-Kellogg C, Montefiori DC, Ackerman ME.

J Immunol. 2016 Dec 15;197(12):4603-4612. Epub 2016 Nov 9.

18.

Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.

Boesch AW, Alter G, Ackerman ME.

Curr Opin HIV AIDS. 2015 May;10(3):160-9. doi: 10.1097/COH.0000000000000149. Review.

19.

HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.

Wren L, Kent SJ.

Hum Vaccin. 2011 Apr;7(4):466-73. Epub 2011 Apr 1. Review.

PMID:
21389779
20.

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.

Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, Wang K, Bao S, Kraemer TD, Rath T, Zeng M, Schmidt SD, Todd JP, Penzak SR, Saunders KO, Nason MC, Haase AT, Rao SS, Blumberg RS, Mascola JR, Nabel GJ.

Nature. 2014 Oct 30;514(7524):642-5. doi: 10.1038/nature13612. Epub 2014 Aug 13.

Supplemental Content

Support Center